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Abstract: Chronic obstructive pulmonary disease (COPD) is a leading cause of death and 
disability worldwide. The Global Burden of Disease study has concluded that COPD will 
become the third leading cause of death worldwide by 2020, and will increase its ranking of 
disability-adjusted life years lost from 12th to 5th. Acute exacerbations of COPD (AECOPD) 
are associated with impaired quality of life and pulmonary function. More frequent or severe 
AECOPDs have been associated with especially markedly impaired quality of life and a greater 
longitudinal loss of pulmonary function. COPD and AECOPDs are characterized by an augmented 
inﬂ  ammatory response. Macrolide antibiotics are macrocyclical lactones that provide adequate 
coverage for the most frequently identiﬁ  ed pathogens in AECOPD and have been generally 
included in published guidelines for AECOPD management. In addition, they exert broad-ranging, 
immunomodulatory effects both in vitro and in vivo, as well as diverse actions that suppress 
microbial virulence factors. Macrolide antibiotics have been used to successfully treat a number 
of chronic, inﬂ  ammatory lung disorders including diffuse panbronchiolitis, asthma, noncystic 
ﬁ  brosis associated bronchiectasis, and cystic ﬁ  brosis. Data in COPD patients have been limited 
and contradictory but the majority hint to a potential clinical and biological effect. Additional, 
prospective, controlled data are required to deﬁ  ne any potential treatment effect, the nature of 
this effect, and the role of bronchiectasis, baseline colonization, and other cormorbidities.
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Introduction
Chronic obstructive pulmonary disease (COPD) affects between 12 and 24 million 
people in the United States, where it is the fourth leading cause of death, accounting 
for over 106,000 deaths in 1996. Worldwide, COPD is the sixth leading cause of death 
(Petty 2000; Ward et al 2000; Halbert et al 2003; Halpern et al 2003; Wouters 2003) 
and is the only condition in the top 10 causes of death with an increasing prevalence 
and mortality (Pauwels et al 2001; Mannino et al 2002; Petty 2000; Stoller 2002). 
The Global Burden of Disease study undertaken by the World Bank and the World 
Health Organization concluded that COPD will become the third leading cause of 
death worldwide by 2020, and its ranking relative for number of disability-adjusted 
life-years lost will increase from 12th to 5th (Gulsvik 2001). Currently, oxygen therapy 
for hypoxemic patients and cigarette-smoking cessation are the only interventions 
known to alter the natural history of COPD.
Although an exact deﬁ  nition of acute exacerbations of COPD (AECOPD) remains 
controversial (Pauwels et al 2004), a generally accepted deﬁ  nition is that of ‘a sustained 
worsening of the patient’s condition, from the stable state and beyond normal day-to-
day variations, that is acute in onset and necessitates a change in regular medication 
in a patient with underlying COPD’ (Rodrigues-Roisin 2000). Acute exacerbations 
of COPD (AECOPD) account for about 13 million ofﬁ  ce visits each year in the US 
(Niederman et al 1999; Sethi 1999; Gonzales et al 2001), and account for 31%–68% International Journal of COPD 2008:3(3) 332
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of the total cost of COPD in the US and Europe (Ward et al 
2000; McGuire et al 2001; Strassels et al 2001; Andersson 
et al 2002; Miravitlles et al 2002). In 1996, acute exacerba-
tions of COPD resulted in the sixth highest use of hospital bed 
days/yr in the US (176 million) and the sixth highest number 
of days lost from work (57.5 million) (Druss et al 2002). As 
such, AECOPDs are a major source of health-care expendi-
ture (Halpern et al 2003). This cost is particularly evident in 
those AECOPDs that require hospitalization (Miravitlles et al 
2002; Oostenbrink and Rutten-van Molken 2004).
The negative implications of AECOPDs have been high-
lighted by numerous investigators. A review of eighteen stud-
ies conﬁ  rmed that AECOPD worsen health-related quality of 
life (HRQL) (Schmier et al 2005). A two-year longitudinal 
study noted that more frequent exacerbations had a deleteri-
ous effect on health status in patients with moderate disease 
(forced expiratory volume in one second [FEV1] 35%–50% 
predicted) (Miravitlles et al 2004). The greatest improvement 
in HRQL occurs during the ﬁ  rst four weeks after a single 
episode, although continued improvement occurs over 26 
weeks. Conversely, recurrence of AECOPD markedly attenu-
ates improvement (Spencer et al 2003).
AECOPDs also result in measurable, albeit modest, acute 
effects on pulmonary function (Seemungal et al 2000). A 
modest improvement in pulmonary function, particularly 
in lung volume, has been reported over the ﬁ  rst several 
weeks after therapy is initiated (Parker et al 2005; Stevenson 
et al 2005) Repeated AECOPDs are associated with loss 
of pulmonary function; the decrement in FEV1 has ranged 
from 7–8 mL/yr for patients with more frequent episodes 
(Donaldson et al 2002; Kanner et al 2001).
Thus, AECOPD are associated with very signiﬁ  cant 
healthcare expenditures, deterioration in HRQL that may 
be sustained, and appreciable deterioration in pulmonary 
function. Accordingly, preventing AECOPDs, or reducing 
their severity, should have favorable clinical, physiological 
and economical effects in COPD patients.
COPD is an inﬂ  ammatory disease
Over the past several years, numerous studies have conﬁ  rmed 
the important role of inﬂ  ammation in the airways and lung 
parenchyma of COPD (Hill et al 1999; Sethi 2000; Aaron 
et al 2001; Gompertz et al 2001; Wedzicha 2002; Pietila 
and Thomas 2003; White et al 2003). Many have advocated 
a central pathogenic role of this inﬂ  ammatory response 
(Hogg et al 2004; Shapiro and Ingenito 2005; Traves and 
Donnelly 2005; Wouters 2005). This inﬂ  ammatory response 
contributes to the increased oxidative stress noted during 
an AECOPD (Tsoumakidou et al 2005). Both neutrophilic 
and eosinophilic inﬂ  ammation have been described, with a 
multitude of inﬂ  ammatory mediators implicated including 
interleukin-8 (IL-8), leukotriene B4 (LTB4), tumor necrosis 
factor-α (TNF-α), granulocyte-macrophage colony stimu-
lating factor (GMCSF), regulated upon activation: normal 
T cell expressed/secreted (RANTES), and endothelin-1 
(ET-1) (Hill et al 1999; Sethi 2000; Gompertz et al 2001; 
Roland et al 2001; White et al 2003). One group followed 
68 patients with COPD and an emphysematous phenotype 
for 2–3 years, with 30 developing an AECOPD associated 
with expectorated sputum adequate for analysis (Fujimoto 
et al 2005). During an AECOPD, total sputum cells, lym-
phocytes, neutrophils, eosinophils, IL-8, neutrophil elas-
tase, eosinophilic cationic protein (ECP), and RANTES 
increased compared to the stable state. Prospective studies 
using bronchoscopic techniques have conﬁ  rmed increased 
expression of RANTES in both the surface epithelium and 
subepithelial lymphomononuclear cells, increased numbers 
of neutrophils, as well as increases in CXCL5 (ENA-87), 
CXCL8 (IL-8), and CXCR2 during an AECOPD (Zhu et al 
2001; Qiu et al 2003; Drost et al 2005). Collectively, these 
data conﬁ  rm a local, inﬂ  ammatory process and increased 
oxidant stress status during exacerbations. Novel pathways 
promulgating this inﬂ  ammatory response have recently been 
deﬁ  ned (Ito et al 2005).
As COPD progresses, the lungs are inﬁ  ltrated by activated 
macrophages (Rutgers et al 2000; Amin et al 2003; Caramori 
and Adcock 2003) and lymphocytes (Saetta et al 1993; 
O’Shaughnessy et al 1997; Hogg et al 2004). Macrophages 
and lymphocytes , are not only increased in the airways and 
alveoli in COPD (Di Stefano et al 2004; Shapiro and Ingenito 
2005), but the prevalence of these two cell types, rather than 
of neutrophils as previously suspected, correlates with the 
severity of airﬂ  ow obstruction (Di Stefano et al 1996, 2001; 
O’Shaughnessy et al 1997; Kemeny et al 1999; Hill et al 
2000; Turato et al 2002; Hogg et al 2004) and emphysema 
(Finkelstein et al 1995; Russell, Culpitt, et al 2002; Russell, 
Thorley, et al 2002).
Macrophages are key cells of the innate immune system, 
secreting cytokines and chemokines when stimulated by 
pathogen-associated molecular patterns (PAMPs). Many of 
the lung lymphocytes are type 1 cytokine-producing CD8 
T cells (Saetta et al 1998, 1999, 2002; Majo et al 2001; 
Grumelli et al 2004). The CD8+ T cells predominance has 
been most evident in studies that used chronic bronchitis as 
an entry criteria (Saetta et al 1997), and is less evident when 
study design selected against chronic bronchitis (Hogg et al International Journal of COPD 2008:3(3) 333
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2004). Although macrophages and CD8+ T cells could 
synergistically contribute to progressive lung destruction 
in COPD in several ways (Barnes et al 2003), the exact 
mechanism remains unproven. The systemic nature of COPD 
and AECOPDs have been recently documented (Agusti 2005). 
Plasma ﬁ  brinogen, IL-6, C-reactive protein, and endothelin-1 
concentrations increase during AECOPDs (Dev et al 1998; 
Wedzicha 2000; Roland et al 2001; Hurst et al 2006).
Lung infections increase 
the inﬂ  ammation of COPD
Various infectious and noninfectious stimuli can stimulate 
the inﬂ  ammatory response associated with an AECOPD. 
Environmental pollutants, including particulate matter and 
nonparticulate gases can provoke an inﬂ  ammatory response 
in-vitro and in in-vivo (Devalia et al 1994; Ohtoshi et al 1998; 
Rudell et al 1999). Epidemiological studies have suggested 
increased respiratory symptoms and mortality during times of 
increased air pollution (Sunyer et al 1993; Garcia-Aymerich 
et al 2000; Sunyer et al 2000). Despite these data, a large 
proportion of AECOPDs are felt to reﬂ  ect infection, whether 
bacterial or viral (Sethi 2004). Viral infections are a well 
recognized cause of AECOPD (Wilkinson et al 2004; Johnston 
2005). The most frequently reported agents include rhinovirus, 
coronavirus, inﬂ  uenza, parainﬂ  uenza, adenovirus, respiratory 
syncytial virus (RSV), and human metapneumovirus (Stott 
et al 1968; Gump et al 1976; Seemungal et al 2001; Greenberg 
2002; Rhode et al 2003; Tan et al 2003; Pletz et al 2004; 
Wedzicha 2004; Hamelin et al 2005).
Atypical infectious agents, including Chalmydia pneu-
moniae, Mycoplasma pneumoniae, and Legionella species, 
have been reported to cause AECOPD, although the majority 
of the data involve C. pneumoniae (Beaty et al 1991; Blasi 
et al 1993; Mogulkoc et al 1999; Karnak et al 2001; Lieber-
man et al 2001; Seemungal et al 2002). The etiologic role of 
bacteria in individual AECOPD episodes has been a subject 
of much controversy (Hirschmann 2000; Murphy et al 2000). 
Recent comprehensive reviews have highlighted the evolution 
of these concepts (Sethi and Murphy 2001; Sethi 2004). Spu-
tum cultures have been the classic methodological approach 
to identifying potentially pathogenic bacteria in AECOPD, 
with the most frequently isolated organisms being nontypeable 
Haemophilus inﬂ  uenzae, Moraxella catarrhalis, and Strepto-
coccus pneumoniae. Other, less frequently identiﬁ  ed organ-
isms include Haemophilus parainﬂ  uenzae, Staphylococcus 
aureus, Pseudomonas aeruginosa and other Gram-negative 
rods. Pseudomonas spp. or other enteric Gram-negative rods 
have been identiﬁ  ed in the sputum of patients with greater 
airﬂ  ow obstruction (Eller et al 1998; Miravitlles et al 1999) 
and prior use of antimicrobial agents (Monso et al 2003).
Bronchoscopic studies using bronchoalveolar lavage or 
protected specimen brush have conﬁ  rmed that potentially 
pathogenic bacteria are identiﬁ  ed in many COPD patients 
at baseline and during AECOPDs (Fagon et al 1990; Monso 
et al 1995; Pela et al 1998; Soler et al 1998). An analysis 
of pooled data from six published studies conﬁ  rmed a high 
frequency of colonization in stable COPD patients in contrast 
with healthy subjects; a clear shift to higher potentially patho-
genic organism load was noted during an AECOPD (Rosell 
et al 2005). Importantly, several groups have demonstrated 
that bacterial colonization, as deﬁ  ned by sputum cultures, 
is associated with a greater sputum and systemic inﬂ  amma-
tory response, more frequent clinical AECOPD episodes 
and greater symptoms and worse health status (Soler et al 
1999; Bresser et al 2000; Hill et al 2000; Patel et al 2002; 
Banerjee et al 2004).
Novel methodological approaches have provided even 
more compelling data implicating bacterial pathogens in 
AECOPD. The longitudinal use of sputum culture and 
molecular typing of bacterial pathogens isolated from sputum 
has demonstrated that acquisition of a bacterial strain with 
which the patient had not been previously infected is asso-
ciated with a greater than twofold increase in the risk of an 
exacerbation (Sethi et al 2002). Although the identiﬁ  cation of 
a new strain of nontypeable H. inﬂ  uenzae was not associated 
with a symptomatic exacerbation in the majority of patients, 
collaborative work has highlighted inherent differences 
in new H. inﬂ  uenzae strains associated with symptomatic 
exacerbations which lead to greater neutrophil recruitment, 
adherence to epithelial cells and greater IL-8 release from 
epithelial cell cultures compared to those not associated 
with such a clinical response (Chin et al 2005). A similar 
approach has conﬁ  rmed the same increased risk of AECOPD 
for M. catarrhalis (Murphy et al 2005).
An immune response to one or more microbial pathogens 
has been utilized recently to deﬁ  ne further the role of bac-
teria in individual AECOPD episodes. This methodological 
approach has been most widely reported for H. inﬂ  uenzae and 
M. catarrhalis (Musher et al 1983; Yi et al 1997; Bakri et al 
2002; Sethi 2004; Murphy et al 2005), and to examine the 
interaction between bacterial and viral infection (Bandi et al 
2003). In one such study, 16/35 exacerbations (46%) were 
associated with evidence of acute viral infection, whereas 11 
(31%) were associated with the development of new serum 
IgG to homologous H. inﬂ  uenzae isolates; evidence of a 
viral infection was identiﬁ  ed in 24/35 exacerbations (79%) International Journal of COPD 2008:3(3) 334
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(Bandi et al 2003). These data show that viral and bacterial 
infections can co-exist during symptomatic AECOPD, 
although antecedent viral infection is not required for 
H. inﬂ  uenzae- associated exacerbations.
Macrolides in COPD
Treatment of AECOPD
Given compelling data that bacterial infection is likely 
etiologic in approximately 50% of AECOPDs, it is not 
surprising that antimicrobial therapy has been intensively 
studied in this disease. Numerous placebo-controlled trials 
of antibiotics in AECOPDs have been published, with 
systematic reviews suggesting a modest treatment effect 
favoring antimicrobial therapy (Bach et al 2001; McCrory 
et al 2001; Saint et al 2001). Saint and colleagues (2005) 
examined nine placebo controlled trials and concluded that 
there was a small but statistically signiﬁ  cant improvement 
with antibiotic therapy, which was especially signiﬁ  cant in 
patients with low baseline ﬂ  ow rates. The American College 
of Chest Physicians, American College of Physicians, and 
the American Society for Internal Medicine systematically 
analyzed 11 randomized, placebo-controlled studies of 
antibiotic treatment and also concluded that antibiotics are 
beneﬁ  cial (Bach et al 2001; McCrory et al 2001; Snow et al 
2001). Additional studies have been published since these 
systematic reviews were published. Allegra and colleagues 
(2001) noted that overall clinical response rate was improved 
with amoxicillin-clavulanate versus placebo in a multi-center 
trial in well-deﬁ  ned AECOPD; response clearly varied by 
the severity of baseline airﬂ  ow obstruction, with the greatest 
difference between placebo and antimicrobial agent noted in 
patients with the lowest FEV1. Nouria and colleagues (2001) 
demonstrated dramatic improvement with oﬂ  oxacin therapy 
compared with placebo in a group of patients with severe 
COPD admitted with respiratory failure.
Based on data such as these, most recent international 
guidelines have incorporated recommendations as to which 
AECOPD patient is more likely to have bacterial infec-
tion likely to beneﬁ  t from an antimicrobial agent (Blasi 
et al 2006). Patients with at least two cardinal symptoms 
of an AECOPD (increase in dyspnea, increase in sputum 
production, and/or change in sputum color) experience a 
beneﬁ  t with antibiotic therapy (Anthonisen et al 1987). An 
exacerbation associated with sputum purulence may also be 
more likely to beneﬁ  t from antibiotic treatment (Stockley 
et al 2000; Wilson 2005). Increasing sputum purulence has 
been clearly associated with bacterial growth in sputum 
samples (Allegra et al 2005; Blasi et al 2006). Measurement 
of serum procalcitonin levels have recently been suggested to 
deﬁ  ne AECOPD patients with a higher likelihood of bacte-
rial infection (Reichenberger et al 2001; Christ-Crain et al 
2004). Hence, the available data suggest that antimicrobial 
therapy provides beneﬁ  t in carefully selected patients with 
more severe disease and more severe exacerbations.
Numerous controlled trials have compared newer agents 
with established ones. These studies have generally been 
designed as noninferiority trials for registrational purposes 
and therefore provide limited comparative information 
regarding clinical response for various antimicrobial classes 
(Miravitlles and Torres 2004; Sethi 2004; Wilson 2005). 
Not surprisingly, clinical response in these trials is gener-
ally similar among different antimicrobial classes. However, 
more recent trials using novel experimental designs have 
suggested interesting differences between different antimi-
crobial classes. For example, in deﬁ  ning ‘bacterial eradica-
tion’ by sputum culture, White and colleagues (2003) noted 
that patients with persistent bacteria after a ten day course of 
antimicrobial therapy exhibited elevated sputum inﬂ  amma-
tory markers. In addition, some investigators have suggested 
that a more rapid resolution of symptoms may be seen with 
quinolones in contrast to comparator agents (Miravitlles et al 
2004; Martinez et al 2005). These data suggest that eradica-
tion of bacterial pathogens may be associated with important 
clinical outcomes.
The most provocative data have revolved around the 
finding that some agents may lengthen the disease-free 
interval (DFI), ie, the time between exacerbations (Anzueto 
et al 1999; Saint et al 2001; Chodosh 2005; Wilson 2005). 
Because antimicrobial therapy that completely eradicates 
bacteria is associated with reduced inﬂ  ammation (White 
et al 2003), such agents should result in greater symptomatic 
resolution and better long-term clinical outcomes (Anzueto 
et al 1999; Chodosh 2005; Wilson 2005). Based on these 
considerations, AECOPD clinical trials have increasingly, 
incorporated an assessment of how different antibiotics affect 
the DFI (Martinez et al 2005). An early study demonstrated 
equivalence between antibiotics in short-term clinical 
response, although post-hoc analysis suggested that failure 
to clear the organism from the sputum post-therapy was 
associated with a shorter DFI (Chodosh et al 1998). Wilson 
and colleagues (2002) noted fewer recurrences of AECOPD 
with gemiﬂ  oxacin (29%) compared to clarithromycin (41.5%, 
P = 0.016). The MOSAIC study investigators contrasted 
moxifloxacin with various comparators (cefuroxime, 
clarithromycin or amoxicillin) (Wilson et al 2004). Although 
all antibiotics resulted in equivalent short-term clinical International Journal of COPD 2008:3(3) 335
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response, moxifloxacin-treated patients required fewer 
additional antibiotics and experienced a longer DFI. In 
contrast, Lode and colleagues (2004) did not demonstrate 
a difference between levoﬂ  oxacin and clarithromycin with 
respect to the DFI, although the patient population was a bit 
less ill. Thus, the effect of antibiotic class on DFI remains a 
crucial endpoint for future studies of AECOPD.
In general, macrolides have provide adequate coverage 
for the most frequently identiﬁ  ed pathogens in AECOPD 
(Martinez 2004), although differences among the compounds 
in H. inﬂ  uenzae activity have been evident. For example, 
azithromycin appears to have improved bacteriologic and 
clinical activity relative to clarithromycin (Martinez et al 
2005). The role of the macrolides in AECOPD therapy remains 
controversial although they have been generally included in 
published guidelines (Balter et al 2003; Pauwels et al; Martinez 
2004; Woodhead et al 2005; Blasi et al 2006). These guidelines 
usually advocate stratiﬁ  cation of patients by likelihood of 
clinical failure, with macrolide therapy suggested for patients 
with milder underlying disease, a low likelihood of infection 
with organisms which are not covered with standard antibiotic 
regimens (eg, P. aeruginosa, drug-resistant bacteria), or host 
factors that predict treatment failure.
Macrolides as immunomodulatory agents
Macrolides are macrocyclical lactones consisting of greater 
than 8-membered rings. This very large class ( 2000 
compounds) comprises both natural substances isolated from 
Figure 1 Molecular structure of 14 member macrolides (erythromycin, A), ﬁ  fteen member compounds (azithromycin, B) and a 16 member compound (C) (Jaffe 
and Bush 2001).
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fungi and other organisms, as well as synthetic molecules 
of a similar structure (Jain and Danziger 2004). The most 
commonly, clinically used agents are semi-synthetic 14-, 
15-, or 16-membered ring antibiotics related to erythromycin 
(Figure 1). These include erythromycin, roxithromycin and 
clarithromycin as typical members of the 14-member class, 
and azithromycin as the prototypical 15-member compound 
(Labro 2004). Macrolide antibiotics bind to 50S ribosomes of 
both prokaryotes and eukaryotes, inhibiting transpeptidation 
or translocation of nascent peptides. Macrolides have good 
bioavailability by the oral route, superb tissue penetration, 
favorable side-effect proﬁ  les, and prolonged tissue persis-
tence. For these reasons, and their broad efﬁ  cacy against 
Gram-positive, some Gram-negative, mycobacterial, chla-
mydial, mycoplasmal, and Legionella species, macrolides are 
well established in the therapy of respiratory infections.
Macrolides exert broad-ranging immunomodulatory 
effects on mammalian cells in vitro and in vivo, as 
comprehensively reviewed by others and brieﬂ  y summarized 
in Table 1 and illustrated in Figure 2 (Zalewska-Kaszubska 
and Gorska 2001; Labro 2004; Tsai and Standiford 2004). 
Among their many activities, macrolides have been shown 
to exert effects on a wide range of cells including nasal and 
bronchial epithelial cells, alveolar macrophages, monocytes, 
eosinophils, neutrophils and lymphocytes. The effect on 
signaling pathways including NF-κB and AP-1 (Desaki 
et al 2000, 2004 Kikuchi et al 2002) is evident in Figure 2. 
Macrolides exert a host of effects that collectively limit 
tissue damage by neutrophils. In addition to effects on 
chemoattractants, these include inhibiting their oxidant burst, 
impair ing degranulation, and increasing the rate of neutrophil 
apoptosis. There is also evidence that macrolides decrease 
mucus viscosity (Tamaoki et al 1995), and suppress angio-
genesis (Yasunami and Hayashi 2001). Importantly, all these 
immunomodulatory effects are evident at concentrations 
attainable clini  cally by low-dose administration, and are not 
seen using 16-member macrolides. Most immuno modulatory 
effects are shared by the 14- and 15-member agents, 
although in some cases the effects vary among the individual 
compounds. For example, roxithromycin appears to exhibit 
consistent effects in vitro and in vivo (Agen et al 1993; 
Scaglione and Rossoni 1998). Similarly, clarithromycin 
and azithromycin induce apoptosis of peripheral blood 
lymphocytes to a qualitatively greater extent than josamycin 
(Ishimatsu et al 2004). Hence, macrolides have many 
properties that could mitigate the neutrophilic inﬂ  ammation 
central to airway damage, and might also improve aspects 
of airﬂ  ow obstruction.
Macrolides also exert diverse actions that suppress 
microbial virulence factors (Shryock et al 1998; Pechere 
2001; Wozniak and Keyser 2004). Although P. aeruginosa 
possesses high innate resistance in vitro (MIC   128 μg/ml), 
Table 1 Anti-inﬂ  ammatory and bacterial virulence effects of macrolide antibiotics
Author,   Year Effect
Inoue et al 1992; Oishi et al 1994; Takizawa et al 1997; Kohyama et al 1999; 
Kikuchi et al 2002; Takaki et al 2003; Desaki et al 2004; Reato et al 2004
Down regulates TNF-α, IL-1, IL-4, IL-8 expression by various cell types
Ishizawa et al 2005 ↑ production of β-defensin-1 and β-defensin-2 by epithelial cells
Villagrasa et al 1997 ↓ superoxide and elastase release from stimulated PMNs
Shimane 1997; Khan et al 1999; Suzaki et al 1999; Yamasawa et al 2004 ↓ stimulated release of IL-1β, IL-6, GM-CSF, and TNF-α
Hashimoto et al 2001; Kanai et al 2004 ↓ matrix metalloproteinase-9 expression and activity
Motojima et al 1996 ↓ IL-5-induced increases in eosinophil survival
Keicho et al 1994; Aoshiba et al 1995; Adachi et al 1996; Inamura et al 2000; 
Ogawa et al 2003; Kadota et al 2005
↑ neutrophil, lymphocyte, histiocyte and eosinophil apoptosis
Oda et al 1994; Tsai et al 2004 ↓ neutrophil chemotaxis
Culic et al 2002; Yamasawa et al 2004 ↓ neutrophil survival
Rubin et al 1997; Shimizu et al 2003; Imamura et al 2004 ↓ mucus secretion
Laforce et al 1983; Fost et al 1999; Imamura et al 2005 ↓ methylprednisolone elimination
Baumann et al 2001; Tsang et al 2003 ↓ P. aeruginosa adherence and outer membrane function
Kobayashi 1995; Ichimiya et al 1996; Takeoka et al 1998; Tateda et al 2001; 
Nagata et al 2004; Gillis and Iglewski 2004; Wagner et al 2005
↓ alginate, bioﬁ  lm formation and quorum sensing
Kawamura-Sato et al 2000 ↓ ﬂ  agellin
Abbreviations: IL, GM-CSF, TNF-α, PMN.International Journal of COPD 2008:3(3) 337
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macrolides accumulate within the microbes over time, and 
suppress elaboration of elastase, lecithinase, and pyocyanin. 
Macrolides also alter the structure of LPS and outer membrane 
proteins, with a net effect of decreasing microbial adhesion to 
host cells. By in hibiting alginate production, macrolides destroy 
pseudomonal bioﬁ  lm, facilitating killing by other antibiotics. 
Finally, sub-inhibitory concentrations of macrolides impede 
microbial motility of both P. mirabilis and P. aeruginosa by 
inhibiting ﬂ  agellin synthesis. Importantly, these activities are 
also common to 14- and 15-ring macrolides, and have not 
seen using rokitamycin, a 16-member ring macrolide that 
has potent bactericidal ac  tivity against susceptible organisms. 
Furthermore, differences among individual agents have 
been reported with azithromycin exhibiting the greatest 
effect on quorum sensing (Molinari et al 1993). Given these 
immunomodulatory properties and unique effects on bacterial 
pathogens macrolide antimicrobial agents have the potential to 
serve a unique role in the management of chronic inﬂ  ammatory 
lung disorders, including COPD.
Macrolides in non-COPD chronic 
pulmonary inﬂ  ammatory disorders
Macrolides have increasingly been used for their immuno-
modulatory properties in a wide range of chronic disorders. 
These will not be discussed in detail but results in chronic, 
inflammatory pulmonary disorders will be highlighted 
with a goal of presenting the rationale for their potential 
use in COPD.
Diffuse panbronchiolitis
Diffuse panbronchiolitis (DPB) is a chronic inﬂ  ammatory 
disorder of the respiratory bronchioles and adjacent cen-
trilobular regions. It is seen mainly, but not exclusively, in 
Japan, and presents with chronic cough, exertional dyspnea, 
and reticulonodular inﬁ  ltrates on chest radiography (Koyama 
and Geddes 1997). Chronic sinusitis is almost always noted. 
In fact, in geographical locations where this disease is found, 
the presence of airﬂ  ow obstruction and chronic sinusitis in 
a nonsmoker should immediately raise suspicion of DPB. 
The appearance on high resolution computed tomography 
of the chest is characteristic (Akira et al 1988; Nishimura 
et al 1992). Early in the disease course, H. inﬂ  uenzae and 
S. pneumoniae are cultured from respiratory secretions, while 
in many cases P. aeruginosa is noted in advanced stages 
(Kadota et al 2003).
The majority of investigators have conﬁ  rmed a marked 
increase in neutrophils in BAL ﬂ  uid of DPB patients 
(Ichikawa et al 1993; Mukae et al 1995; Kadota et al 
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2001; Hiratsuka et al 2003). The percentage of neutrophils 
appears to be higher in DPB patients with P. aeruginosa 
infection (Oishi et al 1994). Not unexpectedly, neutrophil 
chemotactic activity is markedly increased in DPB patients 
compared to normal, healthy volunteers (Kadota et al 
1993; Oda et al 1994). Similarly, DPB patients have high 
concentration of IL-8 in BAL ﬂ  uid (Sakito et al 1996), 
particularly in those infected with P. aeruginosa (Oishi 
et al 1994). Importantly, the histologic pattern of DPB 
includes bronchiolar wall thickening with an inﬁ  ltration 
of lymphocytes, plasma cells, and histiocytes (Homma 
et al 1983). Some investigative groups have noted that 
DPB patients have a higher number of lymphocytes and 
a reduced CD4/CD8 ratio compared to patients with idio-
pathic bronchiectasis and healthy subjects (Mukae et al 
1995). β-defensins have noted to be elevated in the BAL 
ﬂ  uid of DPB patients, with the plasma concentration of 
β-defensin 2 (HBD-2) correlating with the concentration 
in BAL ﬂ  uid (Hiratsuka et al 2003). All these ﬁ  ndings 
support a central role for inﬂ  ammation in the pathogenesis 
of DPB, and suggest that Pseudomonas involvement is at 
least associated with more severe involvement, and may 
contribute to an accelerated deterioration.
Prior to the onset of chronic macrolide therapy, the 
prognosis of DPB was dismal, with a 10 year survival of 
approximately 75% in cases without P. aeruginosa infection 
but less than 22% with P. aeruginosa infection (Koyama 
and Geddes 1997; Kudoh et al 1998). In the mid-1980’s, 
Kudoh and colleagues ﬁ  rst noted that erythromycin therapy 
improved outcome in DPB (Kudoh et al 1984; Kudoh et al 
1987). Subsequent case series (Koyama and Geddes 1997) 
and a randomized, placebo-controlled trial conﬁ  rmed this 
beneﬁ  cial effect (Yamamoto 1991). Importantly, this favor-
able effect was independent of the presence of P. aeruginosa 
infection (Sawaki et al 1986; Nagai et al 1991) or the pres-
ence of chronic respiratory failure (Ohno et al 1993). In addi-
tion to erythromycin, beneﬁ  cial results have been conﬁ  rmed 
with clarithromycin (Takeda et al 1989), roxithromycin 
(Ashitani et al 1992; Nakamura et al 1999), and azithromycin 
(Kobayashi et al 1995).
Increasing mechanistic insight on the clinical effects of 
macrolide therapy in DPB has become available. Improved 
symptoms, pulmonary function and arterial blood gases 
have been noted regardless of the presence of Pseudomonas 
infection, although there appears to be less marked improve-
ment in pulmonary function in patients in whom bacteria 
persist after macrolide therapy, compared to those in whom 
sputum cultures become negative (Fujii et al 1995). As such, 
the effect of macrolides is unlikely to exclusively reﬂ  ect an 
antibacterial effect, as clinical improvement may be seen 
despite lack of change in bacterial isolates or number in at 
least 50% of treated patients (Kadota et al 2003; Nakamura 
et al 1999).
Numerous investigators have demonstrated favorable 
effects of macrolide therapy on the inﬂ  ammatory process 
in DPB. It is unlikely that the effect is purely a result of 
the antibacterial activity of the macrolide, because the 
maximal serum and sputum levels of erythromycin have 
been documented to be below the MICs of the clinically 
identiﬁ  ed isolates (H. inﬂ  uenzae and P. aeruginosa) (Nagai 
et al 1991). Supporting an anti-inﬂ  ammatory effect, clinical 
treatment with a macrolide has been shown to decrease 
neutrophils (Ichikawa et al 1993; Kadota et al 1993; Oda 
et al 1994; Oishi et al 1994; Fujii et al 1995; Nakamura 
et al 1999; Hiratsuka et al 2003), neutrophil chemotactic 
activity (Kadota et al 1993; Oda et al 1994), neutrophil-
derived elastolytic-like activity (Ichikawa et al 1993), and 
concentrations of IL-8 and LTB4 (Nakamura et al 1999). 
The latter has been shown to be independent of the ability 
to ‘eradicate’ organisms from sputum culture. However, 
patients in whom bacteria persist despite chronic macrolide 
therapy are less likely to experience improvement in BAL 
ﬂ  uid neutrophil percentage (Fujii et al 1995). In addition, 
macrolide therapy decreases the percentage of BAL 
lymphocytes and BAL concentration of HBD-2, which 
suggests a primary effect on the underlying pathogenic 
process (Hiratsuka et al 2003). In summary, these data 
confirm that marked beneficial effects are seen with 
macrolide therapy in DPB patients, and these effects likely 
reﬂ  ect the anti-inﬂ  ammatory properties of these agents 
and in addition to potential antimicrobial effects. The 
similarities to potential effects in COPD are evident.
Macrolides in asthma
Asthma has a number of biological features that are distinct 
from COPD (Douwes et al 2002; Sutherland and Martine 2003). 
Macrolide antibiotics have been utilized in asthma for more 
than forty years. For example, troleandomycin (TAO) was 
extensively studied as a steroid-sparing agent in asthma (Niven 
and Argyros 2003), with inconclusive results (Evans et al 
2003). Other investigators have examined more widely avail-
able macrolide agents. The most widely reported outcome has 
been a modest improvement in bronchial hyperresponsiveness 
(Miyatake et al 1991; Shimizu et al 1994; Kamoi et al 1995; 
Amayasu et al 2000; Kostadima et al 2004). Clinical response 
has been more difﬁ  cult to judge in uncontrolled studies (Garey International Journal of COPD 2008:3(3) 339
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et al 2000). Several controlled trials have been published, as has 
a recent Cochrane systematic review (Richeldi et al 2005). In 
general, these studies have documented modest symptomatic 
improvement but little change in standard spirometric indices 
(Shoji et al 1999; Amayasu et al 2000).
Other investigators have provided mechanistic data 
regarding the effect of macrolide therapy in patients with 
asthma. Kraft and colleagues (2002) noted improved FEV1 
in patients with evidence by polymerase chain reaction 
(PCR) of mycoplasma or chlamydia in upper or lower 
respiratory tract specimens (38/55 patients). PCR-positive 
patients treated with clarithromycin experienced a decrease 
in TNF-α, IL-5 and IL-12 mRNA in BAL ﬂ  uid and TNF-α 
mRNA in airway tissue; PCR-negative patients treated with 
clarithromycin exhibited decreased TNF-α and IL-12 mRNA 
in BAL and TNF-α mRNA in airway tissue. No signiﬁ  cant 
changes were seen in subjects treated with placebo. Black 
and colleagues (2001) conducted a multicenter, multinational 
study of 232 adults with mild to moderate asthma and sero-
logical evidence of C. pneumoniae infection, randomizing 
patients to roxithromycin 150 mg bid or placebo for six 
weeks. A modest increase in peak expired ﬂ  ow was noted 
in the macrolide treated patients after six weeks; daytime 
and nighttime symptoms showed nonsigniﬁ  cant improve-
ments, as did improved quality of life scores. The differences 
between these two studies may reﬂ  ect disparity in patient 
characteristics at baseline, differing macrolides administered, 
and differing deﬁ  nition of an atypical infection. These points 
may be important in interpreting data in COPD patients, in 
whom chronic infection with Chlamydia has been felt to be 
important (Blasi et al 2002).
Macrolides in noncystic ﬁ  brosis 
bronchiectasis
Bronchiectasis is a disorder of the bronchi and bronchioles 
manifesting cough, chronic sputum production, dyspnea, and 
wheezing (Barker 2003). The cornerstones of therapy include 
early identiﬁ  cation and treatment of acute exacerbations, sup-
pression of the microbial load, treatment of underlying condi-
tions, promotion of bronchial hygiene, control of bronchial 
hemorrhage, surgical resection of extremely damaged/focal 
disease and reduction of excessive pulmonary inﬂ  ammation 
(Barker 2003).
It is likely that bronchiectasis involves a vicious cycle 
of infection with subsequent inﬂ  ammation and mediator 
release. Investigators have conﬁ  rmed an intense cellular 
inﬁ  ltrate with mononuclear cells (CD4+ T lymphocytes and 
macrophages), a prominent neutrophilia and increased IL-8 
expression (Gaga et al 1998). Increased expression of IL-8 
and other potent chemoattractants (TNF-α and LTB4) have 
also been reported (Angrill et al 2001; Richman-Eisenstat 
et al 1993; Tsang et al 2000). In addition, patients colo-
nized with potentially pathogenic organisms experience a 
greater inﬂ  ammatory response which includes higher BAL 
neutrophil count and higher BAL concentrations of elastase, 
myeloperoxidase, TNF-α and IL-8 (Angrill et al 2001).
Bronchiectasis patients with P. aeruginosa in the spu-
tum have more severely impaired pulmonary function and 
greater sputum volume (Ho et al 1998). These patients also 
appear to exhibit the highest concentration of TNF-α and 
LTB4 (Tsang et al 2000). It is evident that bronchiectasis 
is characterized by augmented airway inﬂ  ammation that 
appears related to bacterial colonization, organism load and 
differing bacterial species.
A small number of studies have examined the effect 
of chronic macrolide therapy in bronchiectasis unrelated 
to cystic fibrosis. After 12 weeks of roxithromycin (4 
mg/kg bid) children with bronchiectasis and increased 
airway hyperreactivity experienced little change in FEV1 
but experienced improvement in sputum purulence and 
airway responsiveness (Koh et al 1997). In a placebo-
controlled trial, Tsang and colleagues (1999) administered 
erythromycin (500 mg bid) for eight weeks to 11 patients 
with bronchiectasis (Tsang et al 1999). P. aeruginosa was 
identiﬁ  ed at baseline in ten of the patients and H. inﬂ  uenzae 
in the eleventh. Patients treated with macrolides experienced 
an improvement in spirometry and 24-hour sputum volume, 
but no parallel improvement in sputum pathogens, sputum 
leukocytes, or levels of IL-1α, IL-8, TNF-α, or LTB4 (Tsang 
et al 1999). Tagaya and colleagues (2002) noted improved 
sputum production in 16 patients with bronchiectasis (n = 11) 
or chronic bronchitis (n = 5) treated with clarithromycin 
(400 mg/day) compared to patients treated with amoxicillin or 
cefaclor. Davies and Wilson (2004) examined thrice weekly 
(after initial loading) azithromycin therapy in 39 patients 
with bronchiectasis, greater than four exacerbations in the 
previous 12 months, and persistent symptoms. Only modest 
improvements were noted in pulmonary function, although 
symptoms scores and acute exacerbations decreased; these 
ﬁ  ndings were independent of P. aeruginosa colonization. In 
a small, cross-over study, Cymbala and colleagues (2005) 
noted a decrease in acute exacerbation rate and mean 24-hour 
sputum volume, but no change in pulmonary function with 
twice weekly azithromycin therapy for six months. These data 
are particularly germane, given the frequent development of 
bronchiectasis following AECOPD (O’Brien et al 2000) .International Journal of COPD 2008:3(3) 340
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Macrolides in cystic ﬁ  brosis
A robust body of literature has emerged demonstrating that 
macrolide antibiotics are beneﬁ  cial in the treatment of cystic 
ﬁ  brosis (CF) lung disease (Equi et al 2002; Wolter et al 2002; 
Saiman et al 2003; Southern et al 2005). Numerous studies 
have strengthened the conclusion that there is excessive 
inﬂ  ammation in CF airways. Khan and colleagues (1995) 
noted higher inﬂ  ammatory cells and mediators in infants 
with CF, even when no evidence of bacterial infection was 
identiﬁ  ed. This augmented inﬂ  ammatory response may 
be intrinsic to CF airway epithelial cells, as DiMango and 
colleagues (1998) noted that in response to Pseudomonas, 
epithelial cells having mutations in the cystic ﬁ  brosis gene 
(CFTR) elaborated higher levels of inﬂ  ammatory mediators 
than cells with normal CFTR.
As with other inﬂ  ammatory pulmonary disorders, a high 
prevalence of chronic airway infection occurs in CF. P. aeru-
ginosa appears to be the most prevalent organism, with 80% 
of patients infected by 18 years of age (Trulock et al 2003). 
This infection has major consequences, as the survival of CF 
patients harboring Pseudomonas aeruginosa is shorter than 
that of CF patients uninfected by Pseudomonas.
A series of studies have conﬁ  rmed the beneﬁ  t of macrolide 
therapy in CF. Jaffe and colleagues (1998) performed an 
open-label study of daily azithromycin in children with 
CF in the UK, noting a modest improvement in spirometry 
with azithromycin therapy. The first well-constructed 
clinical trial of azithromycin in CF was reported by Wolter 
and colleagues (2002). Sixty CF patients (mean age 27.9 
years) were randomly assigned in a double-blind fashion 
to 250 mg azithromycin daily or placebo for 3 months. A 
modest improvement favoring the macrolide was noted 
in spirometry, the requirement for intravenous antibiotic 
treatment for acute exacerbations, and quality of life. Equi 
and colleagues (2002) performed a randomized, double-
blind, placebo-controlled, crossover study of 41 CF patients 
(age range 8–18 years). Patients received daily azithromycin 
adjusted to body weight or placebo for 6 months. After a 
2-month washout period, patients were crossed over to the 
alternative therapy for 6 months. A modest improvement in 
FEV1 was noted favoring azithromycin; however, there was 
no difference in FVC, FEF25–75, pulmonary exacerbation 
rate, antibiotic use, changes in exercise tolerance, quality of 
well-being, bacterial culture densities, or sputum levels of 
interleukin-8 and neutrophil elastase.
The largest trial of macrolide therapy in CF was completed 
by Saiman and colleagues (2003), who performed a multi-
centered, randomized, double-blinded, placebo-controlled 
study of 185 patients  6 years of age who were chronically 
infected with P. aeruginosa and had a percent predicted 
FEV1   30. Patients were treated with weight-adjusted 
azithromycin dosage. After 24 weeks treatment, the percent 
predicted FEV1 improved in the azithromycin group (4.4%), 
whereas it declined in the placebo group (1.8%, p = 0.001). 
Furthermore, azithromycin-treated patients were less likely to 
experience an exacerbation than those treated with a placebo 
(HR 0.65, 95% CI 0.44–0.95, p = 0.03). Subsequent post-
hoc analyses conﬁ  rmed that the improvement in secondary 
endpoints was independent of the change in FEV1 (Saiman 
et al 2005).
The mechanism for this favorable macrolide effect 
remains controversial and is likely multifactorial (Martinez 
and Simon 2004). There is growing evidence that macro-
lides may be beneﬁ  cial by directly altering P. aeruginosa 
biology (Jaffe and Bush 2001; Nguyen et al 2002; Wagner 
et al 2005). Suggested mechanisms include: (1) microbicidal 
effects on P. aeruginosa that are in stationary as opposed to 
exponential growth phase; (2) reduction in the elaboration 
of virulence factors; (3) alteration in bioﬁ  lm formation; (4) 
decrease in bacterial adherence to epithelial cells; (5) inhi-
bition of bacterial motility; and (6) providing a synergistic 
effect to other antibiotics (Martinez and Simon 2004). It is 
likely that beneﬁ  cial anti-inﬂ  ammatory effects also play a 
role (Table 1) (Jaffe and Bush 2001; Nguyen et al 2002; 
Martinez and Simon 2004).
Macrolides in chronic obstructive 
pulmonary disease
Taken together, the available data conﬁ  rm that a macrolide 
can result in clinical improvement in patients with severe, 
chronic inﬂ  ammatory lung diseases associated with frequent 
bacterial colonization and chronic infection. These data 
provide a rationale for expansion of the study of macrolide 
therapy to other, more common, inﬂ  ammatory airway disor-
ders, including COPD. Given the importance of inﬂ  ammation 
and bacterial infection in the pathogenesis of COPD and its 
exacerbations, it is evident that macrolides may offer unique 
advantages as disease-modifying agents and that such an 
effect could be multifactorial (Figure 3).
This possibility is supported by three older published 
studies. First, a randomized trial contrasting moxiﬂ  oxa-
cin with clarithromycin in acute exacerbations conﬁ  rmed 
clinical response to clarithromycin in 88.4% of patients, 
despite achieving bacteriologic eradication in only 48.8% 
(Wilson et al 1999). An immunomodulatory effect of the 
macrolide was suggested to explain this discrepant ﬁ  nd-International Journal of COPD 2008:3(3) 341
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ing (Wilson 2005). Second, Suzuki and colleagues (2001) 
reported results of an open-label, prospective randomized 
trial of erythromycin therapy (200–400 mg/day) versus 
riboﬂ  avin (10 mg/day) for twelve months in COPD patients 
(FEV1 ~ 1.4 liters). During the course of therapy, the risk and 
frequency of experiencing a common cold using a predeﬁ  ned, 
standardized deﬁ  nition and subsequent acute exacerbations 
were prospectively evaluated. Table 2 enumerates the sig-
niﬁ  cant beneﬁ  ts noted with macrolide therapy. Although the 
results are intriguing, the unblinded data collection limits the 
strength of the conclusions in this study.
Third, Gomez and colleagues (2000) identiﬁ  ed 54 patients 
with a long history of chronic bronchitis ( 10 years), a fre-
quency more than ﬁ  ve episodes per year, and at least two 
respiratory hospitalizations in the previous year. Patients were 
treated with azithromycin 500 mg daily for three days every 
21 days from September through May and were compared 
to a similar, retrospective group of untreated COPD patients. 
Although there were no baseline differences between the 
treated patients and the control patients, over the course 
of follow-up macrolide treated patients experienced fewer 
exacerbations and hospitalizations per year (Table 3). Not 
unexpectedly, during exacerbations the azithromycin treated 
group experienced infection with S. pneumoniae (n = 21), P. 
aeruginosa (n = 6), and K. pneumoniae (n = 3). Interestingly, 
within the ﬁ  rst 15 days of prophylactic treatment, 21 of these 
Table 2 Effect of 12 months of erythromycin therapy on common 
colds and AECOPDs in patients with COPD
Outcome Treatment group p value
Control (riboﬂ  avin) 
(n = 54)
Erythromycin 
(n = 55)
Total common 
colds, N
245 67 0.0002
Total number of 
exacerbations, N
64 14  0.0001
Mild/moderate 
exacerbations
53 14 0.0087
Severe 11 0 0.0007
Total patients 
with one or more 
exacerbations, N
30 67  0.0001
Mild/moderate 20 6 0.0004
Severe 10 0 0.0004
Copyright © 2001. Reproduced with permission from Suzuki T,   Yanai M, Yamaya M, 
et al. 2001. Erythromycin and common cold in COPD. Chest, 120:730–3.
Figure 3 Potential beneﬁ  cial effects of macrolides in COPD patient.
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exacerbations were caused by S. pneumoniae isolates with 
diminished susceptibility to macrolides and penicillins. In the 
control group, the predominant isolates during an exacerbations 
included H. inﬂ  uenzae (n = 29) and S. pneumoniae (n = 9; two 
exhibiting diminished sensitivity to azithromycin). This study, 
although using a suboptimal, uncontrolled design, suggests 
that a beneﬁ  cial response can be seen with chronic macrolide 
prophylaxis in high-risk COPD patients. The mechanism of 
improvement was not addressed, but could be related to the anti-
bacterial activity (particularly with regards to H. inﬂ  uenzae).
More recently, two groups have reported small controlled 
studies. Basyigit and colleagues (2004) randomized 30 
stable male COPD patients (mean age ~69 yrs, FEV1 ~ 36% 
predicted) to clarithromycin (500 mg bid) or placebo for two 
weeks in addition to standardized bronchodilator therapy. 
Although no baseline differences were noted between the 
treatment groups, clarithromycin-treated patients experienced 
signiﬁ  cantly improved sputum inﬂ  ammatory markers (Figure 
4), whereas physiologic studies did not change. The results 
of serum inﬂ  ammatory markers were qualitatively similar in 
the two groups. In a second controlled study, 67 patients with 
moderate to severe COPD (mean age ~ 67 yrs, FEV1 ~43% 
pred) were randomized to three months of clarithromycin 
(500 mg of sustained release preparation daily) or placebo 
(Banerjee et al 2004). In contrast to the previous study, all 
patients were taking inhaled corticosteroids. Clarithromycin 
was associated with a signiﬁ  cant improvement in the St. 
George’s Respiratory Questionnaire (SGRQ) symptom score 
(10.2 units) and the SF-36 Physical Function Score (12.9 
units) but no difference in overall SGRQ score, shuttle walk 
distance, spirometry or CRP levels. During the relatively 
short time of follow-up there were ﬁ  ve total AECOPDs (3 
in the clarithromycin and 2 in the placebo group). No dif-
ference was seen in quantitative sputum cultures obtained 
in the stable state (Figure 5). In contrast to the previous 
study, sputum IL-8, TNF-α, or LTB4 levels did not differ 
between clarithromycin versus placebo treatment, although 
there was a modest macrolide-associated improvement in 
sputum neutrophil differential and neutrophil chemotaxis 
(Banerjee et al 2004).
Other investigators have proposed mechanistic rationale 
for improvement with chronic macrolide therapy in COPD 
patients. Tagaya and colleagues (2002) suggested that 
chronic bronchitis or bronchiectasis patients treated with 
clarithromycin (400 mg qd for seven days) experienced 
greater decrease in sputum volume than patients treated with 
a β-lactam. Parnham and colleagues (2005) treated 16 COPD 
patients (mean FEV1 1.8 liters) with azithromycin (500 mg 
daily) for three days and eight with placebo. Azithromycin 
resulted in an early transient increase in overall nitrite plus 
nitrate concentration, but later (days 11–18) decreases in total 
Table 3 Effect of azithromycin prophylactic therapy in COPD 
patients at high risk of AECOPD and treatment failure
Outcome Treatment group p value
Azithromycin 
(n = 54)
Control 
(n = 40)
Exacerbations/year 187 249  0.0001
Hospitalizations/year 22 45  0.05
Copyright © 2000. Reproduced with permission from Gomez J, Baños V, Simarro E, 
et al. 2000. Estudio prospective y comparative (1994–1998) sobre la inﬂ  uencia del 
tratamiento corto proﬁ  lactico con azitromicina en pacientes con EPOC evolucionada. 
Rev Esp Quimioterap, 13:379–83.
Figure 4 Levels of induced-sputum inﬂ  ammatory markers in clarithromycin- and placebo-treated COPD patients before and after treatment. AT, after treatment; BT, before 
treatment; IL-8, interleukin-8; LTB4, leukotriene B4; TNF-α, tumor necrosis factor-α. *p   0.05 before versus after treatment. Copyright © 2004. Reproduced with permission 
from Basyigit I, Yildiz F, Ozkara SK, et al. 2004. The effect of clarithromycin on inﬂ  ammatory markers in chronic obstructive pulmonary disease: preliminary data. Ann Pharmacother, 
38:783–92.
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blood leukocyte count, serum CRP, IL-8- and oxidative burst 
of isolated blood granulocytes. No difference was noted in 
sputum inﬂ  ammatory markers between azithromycin- treated 
and placebo-treated patients.
There is potential risk to chronic macrolide therapy 
in this patient population. Macrolide use may be 
associated with an increased risk of subsequent infection 
with macrolide nonsusceptible bacteria, particularly 
S. pneumoniae (Klugman and Lonks 2005; Vanderkooi 
et al 2005). An increase in macrolide-nonsusceptible 
S. pneumoniae has been reported with chronic erythromycin 
(Aberg et al 2001; Kasahara et al 2005), clarithromycin 
(Kasahara et al 2005) and azithromycin therapy (Gomez 
et al 2000; Aberg et al 2001). Similarly, these agents may 
be associated with gastrointestinal intolerance (Saiman 
et al 2003; Basyigit et al 2004; Cymbala et al 2005), 
cardiac toxicity (Iannini 2002; Milberg et al 2002), and 
ototoxicity (Haydon et al 1984; Swanson et al 1992; 
Wallace et al 1994). The frequency and severity of these 
toxicities varies with the agent, the dose and duration 
of therapy. These potential complications and the high 
prevalence of medical comorbitidies in COPD patients 
highlight the potential risk of chronic empiric macrolide 
therapy in this patient population.
Conclusions
Macrolide antibiotics have assumed an important role in the 
management of AECOPDs because of their broad-spectrum 
coverage and excellent safety proﬁ  le. Increasingly, data 
are becoming available that macrolides have beneﬁ  cial 
effects that are independent of their antibacterial activity. 
These potent anti-inﬂ  ammatory effects may be particularly 
important in chronic inﬂ  ammatory airway disorders. These 
latter actions may be of greatest beneﬁ  t for selected patients 
with COPD, a disorder characterized by augmented pulmo-
nary inﬂ  ammation at baseline, frequent bacterial coloniza-
tion/infection, and recurrent exacerbations of disease which 
further increase lung inﬂ  ammation.
Figure 5 The effect of clarithromycin and placebo on sputum colony forming units (Cfu) numbers/ bacterial (PPM) isolate. Cfu numbers are logged. Weighted bars indicate 
the mean for the whole group. There was no statistically signiﬁ  cant difference between pre- and post-therapy Cfu numbers for both clarithromycin and placebo groups. NS 
indicates not signiﬁ  cant. Copyright © 2004. Reproduced with permission from Banerjee D, Honeybourne D, Khair OA. 2004. The effect of oral clarithromycin on bronchial 
airway inﬂ  ammation in moderate-to-severe stable COPD: a randomized controlled trial. Treat Respir Med, 3:59–65.
NS NS
Day1 Day1 3 months 3 months
Clarithromycin Placebo
= H.infuenzae,=  S.pneumoniae,=  M.catarrhalis,=  other PPM
11
10
9
8
7
6
5
L
o
g
 
s
p
u
t
u
m
 
c
o
l
o
n
y
 
f
o
r
m
i
n
g
 
u
n
i
t
 
n
u
m
b
e
r
/
b
a
c
t
e
r
i
a
l
 
i
s
o
l
a
t
eInternational Journal of COPD 2008:3(3) 344
Martinez et al
The role of chronic macrolide therapy in these patients 
requires additional study to better deﬁ  ne a series of concerns, 
including:
•  What is the treatment-effect of chronic macrolide therapy 
in COPD patients treated maximally with conventional 
therapies?
•  Do macrolides attenuate baseline inﬂ  ammation or do they 
prevent or attenuate AECOPD episodes?
•  Does the therapeutic effect reﬂ  ect antimicrobial activity, 
an immunomodulatory effect, or both?
•  Does the therapeutic effect vary by host factors, 
including disease severity, presence of bronchiectasis, 
presence of baseline colonization with typical (includ-
ing P. aeruginosa) or atypical pathogens (including 
C. pneumoniae), or the presence of comorbidity?
•  What is the toxicity of chronic therapy in COPD 
patients?
•  What is the risk-beneﬁ  t of macrolide therapy in COPD 
patients?
Resolution of these vital questions will require additional, 
well-designed, placebo-controlled trials. To our knowledge 
three large studies are currently ongoing which should yield 
answers to all or most of these vital questions before wide-
spread use of macrolide prophylaxis can be recommended 
in COPD patients.
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